William Slayton

William Slayton, M.D.

Professor

Department: MD-PEDS-HEMATOLOGY
Business Phone: (352) 273-9120
Business Email: wslayton@ufl.edu

About William Slayton

“Dr. Bill” joined the division in 2002 with a focus on platelet disorders and leukemia. He is now the chief of the division of pediatric hematology/oncology, and also chairs the Children’s Oncology Group clinical trial AALL0622, Improved Targeted Tyrosine Kinase therapy for Ph+ Acute Lymphoblastic Leukemia. His laboratory has interest in how normal and leukemic stem cell interact with the bone marrow microenvironment. Current projects are focused on developing better therapies for Ph+ Acute Lymphoblastic Leukemia and Infant Leukemia. Dr. Bill frequently volunteers at Camp Boggy Creek, has organized wilderness river trips for children who have completed their cancer treatment, has written lymericks, and sings in an A ‘capella group. Dr. Bill is married to Dr. Marci Slayton, a pediatrician, and has three children.

Accomplishments

Hugh and Cornelia Carithers Awards
1992 · University of Florida
Eugene F. Tubbs M.D., J.D. Award
1992 · University of Florida

Board Certifications

  • Pediatric Hematology/Oncology
    American Board of Pediatrics
  • Pediatrics
    American Board of Pediatrics

Clinical Profile

Specialties
  • Pediatrics
Subspecialties
  • Pediatric Hematology-Oncology
Areas of Interest
  • Bladder cancer
  • Bone marrow transplant
  • Breast cancer
  • Cancer – resources
  • Cancer treatment information
  • Colorectal cancer
  • Esophageal cancer
  • Gynecological Cancer
  • Leukemia
  • Leukemia – resources
  • Lung cancer
  • Lymphoma – Overview
  • Melanoma of the eye
  • Non-Hodgkin lymphoma
  • Thrombocytopenia

Publications

2016 Pediatric blood & cancer
2012 Journal of genetic syndromes & gene therapy
2007 Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
2006 Paediatric respiratory reviews
2004 Journal of perinatology : official journal of the California Perinatal Association
2003 Annals of the New York Academy of Sciences
2003 Journal of immunology (Baltimore, Md. : 1950)
2003 Journal of pediatric hematology/oncology
2002 Proceedings of the National Academy of Sciences of the United States of America
Journal of pediatric endocrinology & metabolism : JPEM

Grants

Oct 2020 ACTIVE
NCI-COG PEDIATRIC MATCH (MOLECULAR ANALYSIS FOR THERAPY CHOICE)-PHASE 2 SUBPROTOCOL OF AG-120 (IVOSIDENIB) IN PATIENTS WITH TUMORS HARBORING IDH1 MUTATIONS
CHILDRENS HOSP PHILADELPHIA · Principal Investigator
Jul 2020 ACTIVE
NCI-COG PEDIATRIC MATCH (MOLECULAR ANALYSIS FOR THERAPY CHOICE)-PHASE 2 SUBPROTOCOL OF TIPIFARNIB IN PATIENTS WITH TUMORS HARBORING HRAS GENOMIC ALTERATIONS
CHILDRENS HOSP PHILADELPHIA · Principal Investigator
May 2020 ACTIVE
A Phase III Randomized Trial for Patients with de novo AML using Bortezomib and Sorafenib (IND#114480; NSC#681239, NSC#724772) for Patients with High Allelic Ration FLT3/ITD
CHILDRENS HOSP PHILADELPHIA · Principal Investigator
Mar 2020 ACTIVE
AN OPEN-LABEL FEASIBILITY STUDY TO ASSESS THE SAFETY AND PHARMACOKINETICS OF ENASIDENIB IN PEDIATRIC PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (R/R-AML) WITH AN ISOCITRATE DEHYDROGENASE-2 (IDH2) MUTATION
CHILDRENS HOSP PHILADELPHIA · Principal Investigator
Jan 2020 ACTIVE
A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727, IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis
CHILDRENS ONCOLOGY GROUP · Principal Investigator
Oct 2019 ACTIVE
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy (NCORP funding)
CHILDRENS ONCOLOGY GROUP · Principal Investigator
Oct 2019 ACTIVE
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy (NCTN funding)
CHILDRENS ONCOLOGY GROUP · Principal Investigator
Oct 2019 ACTIVE
A Phase 3 Randomized Study of Selumetinib Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)
CHILDRENS HOSP PHILADELPHIA · Principal Investigator
Oct 2019 – Sep 2020
Dolls, Books, Pill crushers, and thermometers
UF MEDICAL GUILD · Principal Investigator
Aug 2019 ACTIVE
A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphobl
CHILDRENS ONCOLOGY GROUP · Principal Investigator
Jul 2019 ACTIVE
FLDOH CMS Hematology/Oncology – COQXE A4
FL DEPT OF HLTH CHILDRENS MED SERVS · Principal Investigator
May 2019 ACTIVE
NIH COG Chair Grant
CHILDRENS HOSP PHILADELPHIA · Principal Investigator
May 2019 ACTIVE
Work Order to the Master Subaward Agreement for Non-Industry Funding Sources between The Children's Hospital of Philadelphia Contracting on behalf of the Children's Oncology Group ("CHOP") and University of Florida ("Subcontractee")
CHILDRENS HOSP PHILADELPHIA · Principal Investigator
May 2019 ACTIVE
Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Heart Failure (PREVENT-HF): A Phase 2b Randomized Placebo-Controlled (Carvedilol) Trial
CHILDRENS ONCOLOGY GROUP · Principal Investigator
May 2019 ACTIVE
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)-Phase 2 Subprotocol of Ensartinib in Patients With Tumors Harboring ALK or ROS1 Genomic Alterations
CHILDRENS ONCOLOGY GROUP · Principal Investigator
May 2019 ACTIVE
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 subprotocol of Ulixertinib in patients with tumors harboring activating MAPK pathway mutations
CHILDRENS ONCOLOGY GROUP · Principal Investigator
May 2019 ACTIVE
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of LY3023414 in Patients With Solid Tumors
CHILDRENS ONCOLOGY GROUP · Principal Investigator
May 2019 ACTIVE
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of Palbociclib in Patients With Tumors Harboring Activating Alterations in Cell Cycle Genes
CHILDRENS ONCOLOGY GROUP · Principal Investigator
May 2019 ACTIVE
Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
CHILDRENS ONCOLOGY GROUP · Principal Investigator
May 2019 ACTIVE
International Phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones
CHILDRENS ONCOLOGY GROUP · Principal Investigator
May 2019 ACTIVE
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients With Tumors Harboring Actionable NTRK Fusions
CHILDRENS ONCOLOGY GROUP · Principal Investigator
May 2019 ACTIVE
A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab with or without Eflornithine (DFMO) (IND# 141913) in Children with Relapsed, Refractory or Progressive Neuroblastoma
CHILDRENS ONCOLOGY GROUP · Principal Investigator
May 2019 ACTIVE
A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
CHILDRENS ONCOLOGY GROUP · Principal Investigator
May 2019 ACTIVE
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
CHILDRENS ONCOLOGY GROUP · Principal Investigator
May 2019 ACTIVE
Phase 2 Trial of Cabozantinib (XL184), an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults With Refractory Sarcomas, Nephroblastoma (Wilms Tumor), and Other Rare Tumors
CHILDRENS ONCOLOGY GROUP · Principal Investigator
May 2019 ACTIVE
A Pilot Study of Rituximab (RTX) and Third Party Latent Membrane Protein (LMP)-Specific Cytotoxic T-Lymphocytes (LMP-TC, IND # 17068) in Pediatric Solid Organ Recipients (SOT) with EBV-Positive CD20-Positive Post-Transplant Lymphoproliferative Disease (PT
CHILDRENS ONCOLOGY GROUP · Principal Investigator
May 2019 ACTIVE
A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Axitinib or Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups
CHILDRENS ONCOLOGY GROUP · Principal Investigator
Mar 2019 ACTIVE
Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND# 117467, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
CHILDRENS ONCOLOGY GROUP · Principal Investigator
Mar 2019 ACTIVE
Phase 3 Accelerated BEP: A Randomised Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours
CHILDRENS ONCOLOGY GROUP · Principal Investigator
Mar 2019 ACTIVE
The Effectiveness of Lactobacillus Plantarum (LBP) in Preventing Acute Graft-Versus-Host Disease (GvHD) in Children Undergoing Alternative Hematopoietic Progenitor Cell Transplantation (HCT)
CHILDRENS ONCOLOGY GROUP · Principal Investigator
Mar 2019 ACTIVE
ARST1431, A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864, IND# 122782) in Patients with Intermediate Risk (IR) Rh
CHILDRENS ONCOLOGY GROUP · Principal Investigator
Mar 2019 ACTIVE
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
CHILDRENS ONCOLOGY GROUP · Principal Investigator
Mar 2019 ACTIVE
Effects of Modern Chemotherapy Regimens on Spermatogenesis and Steroidogenesis in Adolescent and Young Adult (AYA) Survivors of Osteosarcoma
CHILDRENS ONCOLOGY GROUP · Principal Investigator
Oct 2018 – Feb 2019
A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Axitinib or Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups
CHILDRENS ONCOLOGY GROUP · Principal Investigator
Oct 2018 – Feb 2019
NCI-COG PEDIATRIC MATCH (MOLECULAR ANALYSIS FOR THERAPY CHOICE)- PHASE 2 SUBPROTOCOL OF BVD-523FB (ULIXERTINIB) IN PATIENTS WITH TUMORS HARBORING ACTIVATING MAPK PATHWAY MUTATIONS
CHILDRENS ONCOLOGY GROUP · Principal Investigator
Jul 2018 – Feb 2019
Phase 3 Accelerated BEP Trial: A Randomised Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours
CHILDRENS ONCOLOGY GROUP · Principal Investigator
Jun 2018 – Feb 2019
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 subprotocol of Palbociclib in Patients With Tumors Harboring Activating Alterations in Cell Cycle Genes
CHILDRENS ONCOLOGY GROUP · Principal Investigator
Jun 2018 – Feb 2019
The Effectiveness of Lactobacillus Plantarum (LBP) in Preventing Acute Graft-Versus-Host Disease (GvHD) in Children Undergoing Alternative Hematopoietic Progenitor Cell Transplantation (HCT)
CHILDRENS HOSP PHILADELPHIA · Principal Investigator
May 2018 ACTIVE
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
CHILDRENS ONCOLOGY GROUP · Principal Investigator
May 2018 ACTIVE
A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Standard Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL)
CHILDRENS ONCOLOGY GROUP · Principal Investigator
Jan 2018 ACTIVE
Phase 2 Study of Denosumab (IND#127430, NCS#744010), a RANK Ligand Antibody, for Recurrent or Refractory Osteosarcoma
CHILDRENS ONCOLOGY GROUP · Principal Investigator
Jan 2018 – Feb 2019
A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
CHILDRENS ONCOLOGY GROUP · Principal Investigator
Jan 2018 ACTIVE
Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND# 117467, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
CHILDRENS ONCOLOGY GROUP · Principal Investigator
Nov 2017 ACTIVE
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of JNJ-42756493 (Erdafitinib) in Patients With Tumors Harboring FGFR 1/2/3/4 Alterations
CHILDRENS ONCOLOGY GROUP · Principal Investigator
Oct 2017 – Feb 2019
Effects of Modern Chemotherapy Regimens on Spermatogenesis and Steroidogenesis in Adolescent and Young Adult (AYA) Survivors of Osteosarcoma
CHILDRENS ONCOLOGY GROUP · Principal Investigator
Oct 2017 – Feb 2019
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
CHILDRENS ONCOLOGY GROUP · Principal Investigator
Aug 2017 ACTIVE
Health Effects after Anthracycline and Radiation Therapy (HEART): Dexrazoxane and Prevention of Anthracycline-related Cardiomyopathy
CHILDRENS ONCOLOGY GROUP · Principal Investigator
Aug 2017 ACTIVE
Health Effects after Anthracycline and Radiation Therapy (HEART): Dexrazoxane and Prevention of Anthracycline-related Cardiomyopathy
CHILDRENS ONCOLOGY GROUP · Principal Investigator
Aug 2017 – Aug 2022
Health Effects after Anthracycline and Radiation Therapy (HEART): Dexrazoxane and Prevention of Anthracycline-related Cardiomyopathy
CHILDRENS ONCOLOGY GROUP · Principal Investigator
Aug 2017 – Feb 2019
NCI-COG Pediatric Molecular Analysis for Therapy Choice MATCH – Phase 2 Subprotocol of LY3023414 in Solid Tumors
CHILDRENS ONCOLOGY GROUP · Principal Investigator
Jul 2017 – Feb 2019
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
CHILDRENS ONCOLOGY GROUP · Principal Investigator
Jul 2017 ACTIVE
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of Selumetinib (AZD6244 Hydrogen Sulfate) in Patients With Tumors Harboring Activating MAPK Pathway Mutations
CHILDRENS ONCOLOGY GROUP · Principal Investigator
Jul 2017 ACTIVE
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
CHILDRENS ONCOLOGY GROUP · Principal Investigator
Jul 2017 ACTIVE
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Tazemetostat in Patients With Tumors Harboring Alterations in EZH2 or Members of the SWI/SNF Complex
CHILDRENS ONCOLOGY GROUP · Principal Investigator
Jul 2017 ACTIVE
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Vemurafenib in Patients With Tumors Harboring Braf V600 Mutations
CHILDRENS ONCOLOGY GROUP · Principal Investigator
Jul 2017 – Feb 2019
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)-Phase 2 Subprotocol of Ensartinib in Patients With Tumors Harboring ALK or ROS1 Genomic Alterations
CHILDRENS ONCOLOGY GROUP · Principal Investigator
Jul 2017 – Feb 2019
NCI-COG Pediatric Molecular Analysis for Therapy Choice MATCH – Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients With Tumors Harboring Actionable NTRK Fusions
CHILDRENS ONCOLOGY GROUP · Principal Investigator
Jun 2017 ACTIVE
LEAHRN (Late Effects After High-Risk Neuroblastoma) Study
CHILDRENS ONCOLOGY GROUP · Principal Investigator
May 2017 – Feb 2019
Phase 2 Trial of Cabozantinib (XL184), an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults With Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
CHILDRENS ONCOLOGY GROUP · Principal Investigator
May 2017 – Feb 2019
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
CHILDRENS ONCOLOGY GROUP · Principal Investigator
Mar 2017 ACTIVE
A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A(MLL) Gene Rearrangement
CHILDRENS ONCOLOGY GROUP · Principal Investigator
Mar 2017 – Feb 2019
A Pilot Study of Rituximab (RTX) and Third Party Latent Membrane Protein (LMP)-Specific Cytotoxic T-Lymphocytes in Pediatric Solid Organ Recipients (SOT) With EBV-Positive CD20-Positive Post-Transplant Lymphoproliferative Disease (PTLD)
CHILDRENS ONCOLOGY GROUP · Principal Investigator
Oct 2016 – Sep 2017
Thermometers, Pill crushers, and Pill Splitters for Pediatrics Hematology Oncology Patients.
UF MEDICAL GUILD · Principal Investigator
Aug 2016 ACTIVE
A Randomized Phase III Study of Brentuximab Vedotin (SGN-35, IND #117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents
CHILDRENS ONCOLOGY GROUP · Principal Investigator
Jul 2016 – Jul 2021
A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia
CHILDRENS ONCOLOGY GROUP · Principal Investigator
May 2016 – Feb 2019
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864, IND# 122782) in Patients with Intermediate Risk (IR) Rhabdomyosar
CHILDRENS ONCOLOGY GROUP · Principal Investigator
Apr 2016 – Feb 2019
A Phase 1/2 Study of CPX-351 (NSC# 775341) Alone Followed by Fludarabine, Cytarabine, and G-CSF (FLAG) for Children With Relapsed Acute Myeloid Leukemia (AML)
CHILDRENS ONCOLOGY GROUP · Principal Investigator
Apr 2016 – Feb 2019
Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Heart Failure (PREVENT-HF): A Phase 2b Randomized Placebo-Controlled (Carvedilol) Trial
CHILDRENS ONCOLOGY GROUP · Principal Investigator
Nov 2015 – Feb 2019
A Phase II Study of Human-Mouse Chimeric Anti-Disialoganglioside Monoclonal Antibody ch14.18 (Dinutuximab, NSC# 764038, IND# 4308) in Combination with Sargramostim (GM-CSF) in Patients with Recurrent Osteosarcoma
CHILDRENS ONCOLOGY GROUP · Principal Investigator
Nov 2015 – Feb 2019
Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
CHILDRENS ONCOLOGY GROUP · Principal Investigator
Oct 2015 – Oct 2020
The Project:EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
CHILDRENS ONCOLOGY GROUP · Principal Investigator
Jul 2015 – Jun 2020
A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, And Cisplatin (TIP) With High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed By High-Dose Carboplatin And Etoposide (TI-CE) As Firs
CHILDRENS ONCOLOGY GROUP · Principal Investigator
Apr 2015 – Apr 2020
Work order -NCORP
CHILDRENS HOSP PHILADELPHIA · Principal Investigator
Dec 2014 – Feb 2019
Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND# 117467, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
CHILDRENS ONCOLOGY GROUP · Principal Investigator
Oct 2014 – May 2018
Community Central Line Infection Prevention (CCLIP) Tria
JOHNS HOPKINS UNIV · Principal Investigator
Apr 2014 – Apr 2017
ANHL1131
CHILDRENS HOSP PHILADELPHIA · Principal Investigator
Apr 2014 ACTIVE
Larotrectinib (LOXO-101, NSC# 788607, IND#141824) for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute Leukemias
CHILDRENS HOSP PHILADELPHIA · Principal Investigator
Apr 2014 – Feb 2019
NIH COG Chair Grant
CHILDRENS HOSP PHILADELPHIA · Principal Investigator
Apr 2014 – Feb 2019
Work Order To The Master Subaward Agreement For Non-Industry Funding Sources Between The Children's Hospital of Philadelphia Contracting On Behalf of the Children's Oncology Group ("CHOP") And University of Florida ("Subcontractee")
CHILDRENS HOSP PHILADELPHIA · Principal Investigator
Jan 2014 – May 2020
AALL1131
CHILDRENS HOSP PHILADELPHIA · Principal Investigator
Jul 2013 – Dec 2019
Re-MATCH: Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor Adoptive Cell Therapy During Recovery from Myeloablative Chemotherapy and Hematopoietic Stem Cell Transplantation
US ARMY MED RES ACQUISITION · Project Manager
Jan 2013 – Jan 2020
A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND# 69896, NSC# 724772) for Patients with High Allelic Ratio FLT3/ITD.
CHILDRENS ONCOLOGY GROUP · Principal Investigator
Nov 2012 – Nov 2018
P03579
Merck Sharp & Dohme · Principal Investigator
Oct 2012 ACTIVE
Stop Children's Cancer Professorship
UF FOU · Principal Investigator
Apr 2012 ACTIVE
CHOP Work Order – ST. BALDRICKS FOUNDATION SUPPLEMENTAL REIMBURSEMENT
CHILDRENS HOSP PHILADELPHIA · Principal Investigator
Apr 2012 – Jul 2016
COG Chair Grant (U10-CA098543)
CHILDRENS HOSP PHILADELPHIA · Principal Investigator
Feb 2011 – Jan 2016
VPLD and Metformin for relapse
H LEE MOFFITT CANCER CTR · Principal Investigator
Oct 2010 – Jun 2016
CMS Hematology/Oncology Program
FL DEPT OF HLTH CHILDRENS MED SERVS · Principal Investigator
Aug 2010 – Aug 2016
POE08-01
THE CHILDRENS HOSPITAL ASSO · Principal Investigator
Jul 2010 – May 2017
RAD001
DANA FARBER CANCER INST · Principal Investigator
Jul 1996 ACTIVE
EWING'S SARCOMA RESEARCH
UF RESEARCH FOU · Principal Investigator

Patents

Published November 2007
Bone Marrow Stem Cells Promote Regeneration of the Vascular Bone Marrow Niche to Improve Engraftment
#US-2009-0304650-A1

Education

Fellowship – Pediatric Hematology/Oncology
1996 · University of Florida
Internship – Pediatrics
1993 · University of Florida
Residency – Pediatrics
1993 · University of Florida
Medical Degree
1992 · University of Florida
Bachelor of Arts in Biology
1985 · Oberlin College

Contact Details

Phones:
Business:
(352) 273-9120
Emails:
Business:
wslayton@ufl.edu